



## **Dlk1-Dio3 cluster miRNAs regulate mitochondrial functions in Duchenne muscular dystrophy**

Ai Vu Hong, Nathalie Bourg, Peggy Sanatine, Jerome Poupiot, Karine Charton, Evelyne Gicquel, Emmanuelle Massourides, Marco Spinazzi, Isabelle Richard, David Israeli

### **► To cite this version:**

Ai Vu Hong, Nathalie Bourg, Peggy Sanatine, Jerome Poupiot, Karine Charton, et al.. Dlk1-Dio3 cluster miRNAs regulate mitochondrial functions in Duchenne muscular dystrophy. Life Science Alliance, 2022, 10.26508/lsa.202201506 . hal-03454735v1

**HAL Id: hal-03454735**

**<https://univ-evry.hal.science/hal-03454735v1>**

Submitted on 29 Nov 2021 (v1), last revised 23 Nov 2023 (v2)

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Dlk1-Dio3 cluster miRNAs regulate mitochondrial functions in Duchenne muscular dystrophy

Ai Vu Hong <sup>1,2</sup>, Nathalie Bourg <sup>1,2</sup>, Peggy Sanatine <sup>1,2</sup>, Jerome Poupiot <sup>1,2</sup>, Karine Charton <sup>1,2\*</sup>,  
 5 Evelyne Gicquel <sup>1,2</sup>, Emmanuelle Massourides<sup>3</sup>, Marco Spinazzi <sup>4,5</sup>, Isabelle Richard <sup>1,2</sup> and  
 David Israeli <sup>1,2</sup>

<sup>1</sup>Genethon, 91000, Evry, France

<sup>2</sup>Université Paris-Saclay, Univ Evry, Inserm, Généthon, Integrare research unit UMR\_S951,  
 91000, Evry, France.

10 <sup>3</sup>CECS, I-STEM, UEVE INSERM UMR861, AFM, Corbeil-Essonnes, France

<sup>4</sup>Neuromuscular Reference Center, Department of Neurology, CHU d'Angers, France

<sup>5</sup>Institute of Neurobiology and Neuropathology CHU d'Angers, France

\*: Present address: Erytech, 69008 Lyon, France

15 **Corresponding Author:**

**David Israeli**

Généthon, 1 rue de l'Internationale, 91000 Evry, France

Tel: +33 (0)1 69 47 29 67

20 E-mail: Israeli@genethon.fr

**Keywords:** Duchenne Muscular Dystrophy; LGMD; muscle; miRNA; DLK1-DIO3; imprinting; mitochondria; oxidative phosphorylation; metabolism

## Abstract

**Background.** Duchenne Muscular Dystrophy (DMD) is a severe muscle disease caused by impaired expression of dystrophin. While mitochondrial dysfunction is thought to play an important role in DMD, the mechanism of this dysfunction remains to be clarified. We recently identified in DMD and in other muscular dystrophies the upregulation of a large number of the Dlk1-Dio3 clustered miRNAs (DD-miRNAs), in both the muscle and the serum. The objective of the present study was to define the biological functions of DD-miRNAs in skeletal muscle, particularly in the context of muscular dystrophy.

**Methods.** DD-miRNAs expression pattern was characterized *in vitro* and *in vivo*, in normal and dystrophic situations. Epigenomic characterization was performed, to elucidate the molecular control of DD-miRNAs dysregulation. The biological effect of muscle DD-miRNAs dysregulation was investigated by an *in vivo* simultaneous **overexpression** of 14 DD-miRNAs in the wild-type muscle, together with CRISPR-Cas9-based **knockdown** of the entire DD-miRNA cluster in an iPS-derived myotubes. Omics data and bioinformatics tools were used for the prediction of DD-miRNAs biological functions, and functional characterization of mitochondrial pathways was performed.

**Results.** We found that DD-miRNAs dysregulation is not specific to DMD since observed in mouse models for other muscular dystrophies. We showed that DD-miRNAs expression in mdx, is reduced in satellite cells, but highly upregulated in regenerating myofibers, suggesting a myofibers origin of DD6miRNA upregulation in muscular dystrophy in both muscles and serum. We demonstrated that upregulation of DD-miRNAs in the dystrophic muscle is controlled epigenetically by DNA and histone methylation ( $p < 0.0001$  and  $p = 0.001$ , respectively) at the Intergenic Differentially Methylated Region (IG-DMR) of Dlk1-Dio3 locus. Transcriptomic analysis revealed a substantial overlap between the dystrophic muscle of

the mdx mouse and the normal muscle that overexpressed 14 DD-miRNAs. Bioinformatics analysis predicted that DD-miRNAs could regulate mitochondrial functions. The ectopic overexpression of 14 DD-miRNAs, in the healthy muscle, resulted in a drastic downregulation of mitochondrial oxidative phosphorylation (OxPhos) (NES=-2.8, p=8.7E-17), similarly to the level in dystrophic muscles of mdx mice and DMD patients (NES=-2.88, p=7.7E-28). Knocking down the entire DD-miRNA cluster in iPS-derived myotubes resulted in increased mitochondrial OxPhos expression and activities.

**Conclusions.** The present study provides evidence for the modulation of mitochondrial activity in the dystrophic muscle by the upregulated DD-miRNAs and supports an updated model for mitochondrial dysfunction in DMD. The regulation of mitochondrial OxPhos by DD-miRNAs may have a broader impact beyond DMD in physiological and pathological situations of muscle adaptation and regeneration.

## INTRODUCTION

Duchenne Muscular Dystrophy (DMD) is an X-linked severe progressive muscle disease caused by mutations in the *Dmd* gene that codes for the dystrophin protein. The disease severely affects the motor function and leads to the premature death of the patient, primarily due to respiratory and cardiac failures <sup>1</sup>. In striated muscle, dystrophin and its associated proteins link the intracellular cytoskeletal network and the extracellular matrix to stabilize myofibers. The lack of dystrophin protein results in a structural defect in the sarcolemma and impairs contractile activity. The lack of dystrophin promotes a pathological cascade, that includes calcium overload, hyperactive proteases, oxidative stress, mitochondrial dysfunction and damages, chronic inflammation, muscle degeneration and impaired regenerative capacity, and in advanced stage the replacement of the contractile tissue by fibrotic and fat tissues <sup>1,2</sup>.

We recently identified a coordinated dysregulation in DMD of many miRNAs originated from Dlk1-Dio3 locus <sup>3-5</sup>. The imprinted Dlk1-Dio3 locus hosts the largest miRNA mega-cluster in the human genome, in addition to other non-coding RNAs and three protein-coding genes (*Dlk1*, *Rtl1*, and *Dio3*) and is highly conserved in the mammalian genomes <sup>6</sup>. Dlk1-Dio3 miRNAs (DD-miRNAs) were shown to play a critical role in fetal development and postnatal growth <sup>6-8</sup>. Initial indications for DLK1-DIO3 locus involvement in the muscular system came from the identification of the muscular hypertrophy Callipyge phenotype in the sheep<sup>9</sup>. Consistently, patients carrying a genetic defect in Dlk1-Dio3 locus present hypotonia and muscle metabolic deficiencies. However, the biological functions of these miRNAs in the context of muscular dystrophy remains relatively unexplored.

In the present study, we showed that the DD-miRNA dysregulation is associated to muscle regeneration since, in addition to DMD, it was found also in several mouse models for other muscular dystrophies, as well as in regenerating normal muscle. We used the mdx mouse model for the investigation of DD-miRNAs expression control and biological functions in DMD. We

found that in the dystrophic muscle the upregulation of DD-miRNAs correlates with epigenetic changes at two regulatory regions of the Dlk1-Dio3 locus. Combined analysis of DD-miRNAs target prediction, and of the transcriptome of dystrophic muscles, suggested that DD-miRNAs may target mitochondrial metabolism, and particularly the oxidative phosphorylation (OxPhos) system. Indeed, *in vivo* overexpression of 14 selected DD-miRNAs, in healthy muscles, drastically reduced mitochondrial OxPhos, and importantly, partly resembled the transcriptome of the dystrophic muscle. Furthermore, knocking down the entire DD-miRNAs cluster in hiPSC-derived myotubes resulted in increased RNA and proteins expression of OxPhos components, and the increased activity of the mitochondrial 1-5 complexes. Our data suggesting a cooperative regulation by DD-miRNAs of mitochondrial functions in DMD and possibly in other situations of muscle regeneration.

## MATERIALS AND METHODS

### Animal care and use

All animals were handled according to French and European guidelines for human care and the use of experimental animals. All procedures on animals were approved by Genethon's ethics committee under the numbers CE10-122, CE10-123, CE10-124, CE10-127, and CE12-039. C57Bl10, C57Bl6, and C57BL/10ScSn-Dmd<sup>mdx</sup>/J mice were obtained from Charles River laboratories. Mice were housed in a SPF barrier facility with 12-h light, 12-h dark cycles, and were provided with food and water ad libitum. Only male mice were used in the present study. The animals were anesthetized with a mix of ketamine (100 mg/kg) and xylazine (10 mg/kg), or with isoflurane, for blood samples. For intramuscular injections, a volume of 25  $\mu$ l containing 1.0E10vg AAV vectors was injected into each TA muscle. For the duration of the

study, all animals were observed at least once a day. All animals were weighed on the day of treatment as well as on the day of the necropsy.

### **AAV vectors expressing multiple miRNAs**

The 14 pre-miRNA sequences were obtained from UCSC, spanning 100 nucleotides before and after the mature miRNA sequences. The pre-miRNA sequences were then arranged consecutively which respect the genomic sequences of the miRNAs. Two or three pre-miRNAs were used per AAV construct.

### **Transcriptomic analysis**

Differentially expressed genes were identified by DESeq2 R package. Pathway analysis was performed in R-Studio, either by over-representation methods using Gene Ontology and ReactomePA or functional class scoring using Geneset Enrichment Analysis (GSEA).

### **Computational prediction of DD-miRNA targets**

Targets of Dlk1-Dio3 miRNAs were predicted by using R package miRNAAtap<sup>10</sup>, compiling data from five public databases: DIANA, Targetscan, PicTar, Miranda, and miRDB. The targets used in subsequent analysis are genes predicted by at least two databases.

### **Genomic deletion using the CRISPR/Cas9 and screening for bi-allelic deletion clones**

Different combinations of single-guide RNAs (sgRNAs) targeting two ends of IG-DMR region were tested in 911 human cells for cutting efficacy. Selected sgRNAs were then used to delete IG-DMR region in hiPS cells, followed by clonal selection and myogenic differentiation.

### **Data presentation and statistical analysis**

The results were presented as mean  $\pm$  standard error of the mean (SEM) of at least three replicates. PRISM 7.01 program (GraphPad) and R-Studio (version 4.0.3) were used for statistics. Comparisons between two groups were done using student t-test. Comparisons between two groups according to the levels of two categorical variables were done using two-way ANOVA. Significance was defined as \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

Other material and methods are provided in the **extended materials and methods** in the supplemental material.

## RESULTS

### Upregulation of DD-miRNA in regenerating myofibers and in the serum is associated to muscle regeneration

In previous studies, we identified a dysregulation of a large number of miRNAs of the Dlk1-Dio3 cluster (DD-miRNAs) in the serum of the GRMD dog, a model for DMD<sup>4</sup>, and in the plasma of DMD patients<sup>3</sup>. In the GRMD model, we found that DD-miRNAs are among the most highly upregulated miRNA, not only in the circulation, but also in the muscle<sup>5</sup>. In the present study, we confirmed this observation across species. In particular, we quantified DD-miRNAs in muscle biopsies of DMD patients (**Figure 1A**,  $n=4$ ), and mdx mouse (**Figure 1B**, 5-week-old mice, diaphragm muscle,  $n=6$ ) and confirmed their upregulation in the dystrophic muscle. Thus, DD-miRNAs are upregulated in DMD in the muscles and in the serum.

To define whether these dysregulations are specific to DMD, we quantified DD-miRNAs in serum and muscle biopsies of a collection of mouse models for limb-girdle muscular dystrophies, including LGMDR1 (calpainopathy), LGMDR5 (gamma sarcoglycanopathy) and LGMDR3 (alpha sarcoglycanopathy). Upregulation of DD-miRNAs was identified in both serum and muscles of all these disease models ( $n=4$ , **Figure 1C-D**) and, interestingly, in a



severity dependent manner. DD-miRNAs are therefore expressed in the healthy muscle and upregulated further in distinct muscular dystrophies. Next, we analyzed the expression of DD-miRNAs during muscle regeneration in the model of myotoxin-induced injury. The levels of a collection of DD-miRNAs, along with other maternal and paternal transcripts from the same locus (*Meg3*, *Rian*, *Mirg*, *Dlk1*, and *Rtl1*), increased gradually from day 7 to 14 post-injury, confirming upregulation in the regenerating muscle independently of a genetic defect (**Figure 1E**).

In addition to the muscle, the postnatal expression of DD-miRNAs was shown also in the brain<sup>11,12</sup>. In agreement, we found the highest expression DD-miRNAs in the brain, which was followed by the skeletal muscle, and a much lower levels in all other tissues and organs. However, the upregulation of DD-miRNAs in muscular dystrophy was found in the mdx mouse only in the skeletal muscle (**Supplemental Figure 1A**). Thus, serum upregulation of DD-miRNAs in this mouse model is likely originating from the muscle. Since the skeletal muscle is a complex tissue composed of several cell types, we attempted to clarify which are the specific sites and cells that are expressing the DD-miRNAs within the muscle. We performed *in situ* hybridization (ISH) of two relatively highly expressed DD-miRNAs, miR-127-3p and miR-379-5p, in the diaphragm of 5-week-old mdx mice and their respective controls. Both miRNAs presented similar pattern of high expression in muscle areas of intensive muscle regeneration, composed of small-diameter centranucleated regenerating myotubes and of muscle mono-nucleated cells (MMNC) (**Figure 1F**), thus both MMNC and regenerating myotubes may contribute to the upregulation of DD-miRNAs in the serum.

To distinguish between these two possibilities (for the origin of upregulation in the dystrophic muscle), we profiled DD-miRNAs in FACS-sorted MMNC subpopulations, and *in vitro* in differentiated myotubes. DD-miRNAs expression was not upregulated in any of the mdx-derived MMNC fractions. On the contrary, in agreement with<sup>13</sup>, DD-expression was repressed

in the freshly-sorted satellite cells (QSC) (**Supplemental figure 1B**). To test DD-miRNAs expressions in myotubes, satellite cells from hind-limbs muscles of mdx and control mice were FACS-sorted, grown, and differentiated *in vitro* for 5 days. Profiling of three representative DD-miRNAs confirmed their reduced level in mdx QSC. DD-miRNAs expression then  
5 dropped down sharply at the beginning of the differentiation stage. Expression however raised up in day-5 differentiated myotubes, to a level significantly higher in mdx than in controls (**Figure 1G**, n=3). Thus, muscle upregulation of DD-miRNAs is seemingly coming from regenerating myofibers and not from the MMNC. In summary, the postnatal expression of DD-miRNAs in the mouse is the highest in brain, followed by skeletal muscle. In various muscular  
10 dystrophies, DD-miRNAs expression is upregulated both in muscle and serum. In the muscle, the upregulation is occurring in the regenerating fibers. The data could also suggest that serum upregulation of DD-miRNAs is linked to their increased expression in regenerating myotubes, likely through an active mechanism rather than passive leakage through damaged sarcolemma, since these regenerated fibers are not in the process of degeneration.

## 15 **Epigenetic modifications control DD-miRNAs upregulation in mdx muscle**

We then investigated the upstream regulation of the DD locus. Two central regulatory regions are known to control the expression of maternal transcripts of the Dlk1-Dio3 imprinted locus: the Intergenic Differentially Methylated Region (IG-DMR) and the Meg3 Differentially Methylated Region (Meg3-DMR), which are known to be subjected to histone modifications  
20 and DNA methylation<sup>6,14</sup>. First, we used the C2C12 myoblast cell line in order to test if the Dlk1-Dio3 locus is epigenetically controlled in the myogenic lineage. C2C12 cells were incubated with 5-Azacytidine, a DNA methylation inhibitor, and with Givinostat and TSA, both being histone deacetylation (HDAC) inhibitors. The inhibition of DNA methylation and of HDAC activity resulted in significant increased expression of genes of the Dlk1-Dio3 locus

(**Supplemental Figure 2A-C**), indicating that both types of epigenetic modifications participate in the control of gene expression in the Dlk1-Dio3 locus in the myogenic lineage.

We then asked if epigenetic changes of the mdx diaphragm are occurring specifically at the Dlk1-Dio3 locus. Bisulfite sequencing demonstrated a reduction in DNA methylation level at

IG-DMR (**Figure 2A**,  $p=1.06E-05$ , two-way ANOVA test), but not Meg3-DMR. Chromatin immuno-precipitation (ChIP) followed by qPCR was used for the detection of histone modifications of IG-DMR and Meg3-DMR regulatory regions. We found a significantly reduced percentage of H3K27me3 histone repressive marker in both IG-DMR ( $p=0.001$ , two-way ANOVA test) and Meg3-DMR ( $p=0.009$ , two-way ANOVA test) in the mdx diaphragm compared to control (**Figure 2B**).

### ***In vivo* DD-miRNAs overexpression reduces muscle mass**

To investigate the functions of DD-miRNAs *in vivo* in skeletal muscle and since miRNAs often act synergistically, we therefore overexpressed simultaneously a selection of miRNAs in the wild-type muscle using recombinant Adeno-Associated Virus (AAV-derived vectors). We selected 14 miRNAs based on their expression and dysregulation levels in dystrophic serum, skeletal muscle and quiescent satellite cells (**Supplemental Figure 3A, Supplemental Table 4, Figure 3A**).

The mouse pre-miRNA sequences of these 14 miRNAs were sub-cloned into five AAV expression vectors (four that contained each a tandem of three DD-miRNAs and one with two DD-miRNAs) that co-express the GFP protein, as schematically described in (**Figure 3B**). These five AAV vectors were co-administrated by an intramuscular (IM) injection into the tibialis anterior (TA) muscle of 4-week-old C57Bl6 control mice. An AAV vector with the same expression cassette but devoid of pre-miRNA sequences served as negative control. The protocol included two time points (1 and 3 months post-injection) with a muscle function tests

at the 3-month group (**Figure 3C**). Analysis of the injected muscles confirmed the overexpression of all injected DD-miRNAs (**Supplemental Figure 3B**) to a comparable level to endogenous DD-miRNAs in the diaphragms of the mdx mice and of DMD muscle biopsies (**Supplemental Figure 3C**). DD-miRNAs overexpressing TA muscles presented a significantly reduced muscle mass at both 1 and 3 months after injection (49.13% and 43.15%, respectively; **Figure 3D**). At 3 months post injection, *in situ* mechanical force measurement showed that both absolute value of maximum tetanic force and maximum twitch force of DD-miRNA overexpressed muscles significantly dropped at 27.2% and 29.1%, respectively (**Figure 3E, G**, n=5). When reported to the muscle mass, the normalized values of tetanic force and twitch force were slightly higher in the presence of DD-miRNAs (**Figure 3F, H**, n=5), indicating that the reduction in mechanical force was due to the loss of muscle mass.

### **The transcriptomic changes following ectopic overexpression of 14 DD-miRNAs overlap with the dysregulation in mdx dystrophic muscle**

To understand to which extent the dysregulation of DD-miRNAs contributes to the transcriptomic changes of the dystrophic muscle, we compared the transcriptomic profile of the dystrophic muscles to that of the healthy muscles overexpressing DD-miRNAs. In the dystrophic diaphragm, 8309 differentially expressed genes (DEGs) were identified (n=4, BH-adjusted p-value < 0.05) (**Figure 4A, C**). In one-month treated muscles injected with AAV-DD-miRNAs, DD-miRNAs overexpression resulted in 2048 DEGs (n=3, BH-adjusted p-value < 0.05) (**Figure 4A, D**), of which 74.2% (1520 out of 2048) were also dysregulated in the dystrophic muscle (**Figure 4A**). Furthermore, a highly significant correlation was observed between the level of dysregulation of these 1520 common DEGs within the two datasets (Pearson correlation test, R=0.73, p-value < 2.2E-16) (**Figure 4B**). These data indicate that the majority of changes driven by DD-miRNAs overexpression in the normal muscle are included in the transcriptomic dysregulation seen in the mdx muscle. Of note, we found that many of

the highly correlating repressed transcripts are of mitochondrial genes (**Cyan dots in Figure 4B**).

Next, gene set enrichment analysis (GSEA) was utilized to interpret the transcriptomic changes at the pathway level <sup>15</sup>. As expected, pathways related to immune response and fibrosis progression were found highly upregulated in the mdx muscle, and many metabolic pathways were significantly downregulated (**Figure 4E**). Strikingly, high-level overlap of pathway dysregulation was identified in the DD-miRNAs overexpressed muscle, compared to negative controls (**Figure 4F; Supplemental Table 5**). Consistent with the down-regulation of mitochondrial transcripts, the pathway analysis revealed downregulation of mitochondrial pathways and particularly of oxidative phosphorylation, which was by far the most downregulated pathway in both systems (the dystrophic muscle and the healthy muscles overexpressing DD-miRNAs).

Taken together, the data supported that about 75% of the transcripts which are potentially repressed by DD-miRNAs, may participate in significant gene regulation in the dystrophic diaphragm of the mdx mouse, which potentially account to up to approximately 20% of the diaphragm transcriptome dysregulation.

### **Dlk1-Dio3 miRNAs affect metabolic pathways in the skeletal muscle**

Next, we employed a bioinformatics approach to identify potential 14 selected DD-miRNAs' target genes. First, five prediction tools (DIANA, Targetscan, PicTar, Miranda, and miRDB) were used, generating 5295 candidate targets predicted by at least two different tools (**Figure 5A**). The list of these predicted targets was subsequently crossed with the lists of genes downregulated in DD-miRNAs injected muscles and in the mdx diaphragm (that naturally overexpresses the DD-miRNAs). The analysis resulted in 269 DD-miRNAs predicted targets (**Supplemental Table 6, Figure 5A**). These 269 genes were subjected to gene ontology (GO)

classification, which identified metabolism-related terms at the highest p-values, including mTOR signaling, pyruvate metabolism, TCA cycle and mitochondrial electron transport chain (**Figure 5B**). Downregulation of a selection of these genes was then experimentally validated in the dystrophic muscle (5-week-old mice, diaphragm muscle, n=4) and AAV-DD-miRNAs-  
5 injected TA muscles (n=4) at the levels of mRNA (**Figure 5C**) and protein (**Figure 5D**). These data strongly support that DD-miRNAs are involved in the metabolic adaptive response of the dystrophic muscle.

### **DD-miRNAs affect mitochondrial functions in the dystrophic muscle**

Clustered miRNAs are thought to coordinately regulate genes that are functionally related <sup>16</sup>.

10 In the dystrophic muscle, we have recently shown that one specific DD-miRNA, namely miR-379-5p, is acting on the mitochondrial oxidative phosphorylation pathway <sup>5</sup>. Taken together, we hypothesized that, in the dystrophic muscle, DD-miRNAs might coordinately regulate mitochondrial functions. In order to estimate the global level of mitochondrial adaptation that occurs in the dystrophic muscle, we used our transcriptomic data of the mdx diaphragm and of  
15 the DD-miRNAs overexpressed muscles, combined with the Mitocarta database of mitochondrial genes <sup>17</sup>. Of the 7406 dysregulated (adjusted p-value < 0.05) transcripts in the mdx diaphragm, 788 (10.64%) were found to be mitochondrial. In order to estimate the relative role DD-miRNAs in this mitochondrial adaptive response, we found that of the 2048 dysregulated transcripts in the TA-DD-miRNAs, 265 (12.94%) were found to be mitochondrial  
20 (**Supplemental Figure 4A**), of which 250 (out of 265) were commonly dysregulated in the mdx diaphragm and therefore potentially regulated by DD-miRNAs in the mdx diaphragm. Thus, of the 788 mitochondrial transcripts dysregulated in the mdx diaphragm, about one-third could be impacted by DD-miRNAs. This is however an underestimation, because only 14 of all dysregulated DD-miRNAs <sup>3,4</sup>, were ectopically overexpressed in the TA muscle. We then

attempted to characterize in details the mitochondrial effect of the DD-miRNAs overexpressed muscle as compared to the mdx diaphragm. Mitochondrial DNA copy number (**Figure 6A, D**), citrate synthase levels (**Figure 6B, E**), and resting ATP concentration level (**Figure 6C, F**) were both significantly reduced in mdx compared to WT and in TA-DD-miRNAs compared to TA-Empty control. Immunohistochemistry of cytochrome oxidase (COX) and succinic dehydrogenase (SDH) in mdx diaphragm and TA-DD-miRNAs muscle confirmed a reduction of mitochondrial activities in those two muscles (**Figure 6G-H**). Taken together, the data supports that DD-miRNAs are acting on mitochondrial metabolism in dystrophic muscle. The gene expression and pathway analyses described above indicated that mitochondrial oxidative phosphorylation might be one of the most affected mitochondrial functions downstream to the dysregulation of DD-miRNAs (**Figure 4E-F, Supplemental Figure 4B-C**). We therefore attempted to characterize it further. Similar reduction of OxPhos RNA level was observed in muscle biopsies from two independent large cohorts of young DMD patients compared to its age-matched healthy controls (**Supplemental Figure 4E, G**) (data was taken from GEO accession: GSE6011<sup>18</sup> and GEO accession: GSE38417). As expected, expression level of Meg3 transcripts are highly significantly upregulated within the DMD groups' muscles (GSE6011: n=13/23, p-value=0.0009; GSE38417: n=6/16, p-value<0.0001) (**Supplemental Figure 4D, F**). This data demonstrates a reduced OxPhos and its negative correlation with Dlk1-Dio3 maternal transcripts in muscle biopsies of human DMD patients too.

A western blot analysis demonstrated reduced expression of proteins belonging to all four mitochondrial respiratory chain complexes and ATP synthase in the both mdx versus control diaphragms and DD-miRNAs versus control transduced TA muscle (**Figure 6I**). Of interest, of the five proteins that were monitored in this experiment, two are potential targets of DD-miRNAs (SDHA is a potential target of miR-411-5p, and UQCRC2 is of miR-409-3p) while the other three (CI-NDUFA9, CIV-MTCO1, and CV-ATPA5) are not predicted to be direct



targets of any DD-miRNA. It indicates that the downregulation of OxPhos proteins in the conditions of elevated DD-miRNA in the muscle involved a global downregulation of mitochondrial complexes, rather than (or in addition to) direct targeting by DD-miRNAs. We then tested the activities of the different mitochondrial complexes (normalized to Citrate Synthase activity (CS) – an indicator of mitochondrial mass)<sup>19</sup>. Reduced complex activities were observed in complexes I, II, and IV in both systems, while complex III and V presented reduced activity only in the TA-DD-miRNAs muscles (**Figure 6K-L**). Significant reductions were also detected for the combined activity of complex I+III (NADH cytochrome c oxidoreductase) in both systems.

## 10 Reduction in DD-miRNAs level increases OxPhos expressions and activities

Next, we wanted to ask whether mitochondrial activities could be enhanced by reducing DD-miRNAs expression. Since no viable mouse model exists with a silencing of the entire DD-miRNA cluster, we decided to create *in vitro* myogenic model of reduced DD-miRNAs expression. The M180 human induced pluripotent stem cell (hiPSC) line was selected, because it expresses high level DD-miRNAs throughout *in vitro* myogenesis<sup>20</sup>. Since it was previously shown that maternal Dlk1-Dio3 expression, including DD-miRNAs, was abolished in IG-DMR<sup>-/-</sup> mouse embryonic stem cells<sup>21</sup> we deleted, in M180 iPS, the 11 kb IG-DMR by double-cut CRISPR/spCas9 strategy, with two sgRNAs target the two ends of IG-DMR (**Figure 7A**). Clonal selection was performed and biallelic deletion verified (Supplemental **Figure 5A**). IG-DMR<sup>+/+</sup> (Ctrl) and IG-DMR<sup>-/-</sup> (IG-KO) clones were differentiated *in vitro* into skeletal muscle myotubes (Supplemental **Figure 5B-C**). IG-KO clones showed normal myogenic differentiation capacity, by successfully converting into myotubes (Supplemental **Figure 5C**). However, while complete KO of DD-miRNA levels was seen in the iPS pluripotent state (D0), (Supplemental **Figure 5D**), only partial, but significant, reduction was observed in fully



differentiated myotubes (**Supplemental Figure 5E**), suggesting that, while the DD-miRNA expression is controlled solely by IG initially, additional elements control their expression following maturation. We then investigated the mitochondrial responses in hiPSC-derived myotubes with reduced DD-miRNA levels. At the RNA level, IG-KO clones showed a global upregulation of transcripts of all five OxPhos complexes, although with variation between clones in the level of some genes (n=4, student t-test) (**Figure 7B**). Besides, increased mRNA levels in both IG-KO clones were also seen in two master regulators of mitochondrial biogenesis (Tfam and Ppargc1a), four DD-miRNAs predicted targets (**Figure 7B**), and two validated targets (Eif4g2, Usmg5)<sup>5</sup>. Similarly, the protein levels of five representatives for five OxPhos complexes in the two IG-KO clones showed a global increase compared to the control (**Figure 8C**). More importantly, activities of all five OxPhos complexes in the KO clones increased significantly compared to control (**Figure 7F**). Accumulatively, these results support that reduced DD-miRNAs can enhance mitochondrial activity, particularly the OxPhos system in differentiated myotubes.

## DISCUSSION

In previous investigations, we identified the upregulation of DD-miRNAs in the serum and the muscles of DMD patients and animal models<sup>3-5</sup>. In the present report, we are bringing new evidences supporting a role for the DD miRNA cluster in the regulation of mitochondrial functions in DMD.

**Indications that circulating DD-miRNAs are produced and secreted by the regenerating muscle.** In agreement with previous studies<sup>11,12</sup>, we detected in adult mouse the highest DD-miRNAs expression in the brain, followed by the skeletal muscle. However, activation of expression in the mdx was detected only in the muscle. In addition, induced DD-miRNAs expression was observed in the serum of other mouse models for muscular dystrophy, without brain phenotype, making it unlikely that brain DD-miRNAs contributing significantly to the

upregulation of circulating DD-miRNAs in muscular dystrophy. These data support strongly that regenerating myofibers are mostly responsible for the elevated levels of muscle and circulating DD-miRNAs in muscular dystrophy. The serum profiles of DD-miRNAs over different ages in GRMD dogs <sup>4</sup> and DMD patients <sup>3</sup> revealed a similar expression pattern to the mCK, of reduced dysregulation level beyond the age of 1 year in GRMD <sup>4</sup> and of 12 years in DMD <sup>3</sup>. However, while the dropdown with age in DMD of serum mCK is thought to reflect reduced muscle mass and reduced myofiber degeneration, on the contrary, the dropdown with age of circulating DD-miRNAs is seem to best explained by reduced myofiber regeneration rate, which is consistent with the well-known exhaustion of the muscle regenerative capacity in DMD with evolution of the disease.

### **Epigenetic control of DD-miRNA dysregulation in the dystrophic diaphragm.**

DNA methylation and post-translational modifications of core histones at differentially CpG methylated regions (DMRs) are the most characterized epigenetic mechanisms controlling Dlk1-Dio3 imprinting and expression <sup>6,21,22</sup>. In non-muscular system, the increased expression of DD-miRNA was shown to be associated with DNA hypomethylation <sup>23,24</sup>, and aberrant histone modifications <sup>25</sup> at these DMRs. Epigenetic control was shown to play a key role in the regulation of muscle functions in muscular dystrophy <sup>26,27</sup>. We thus hypothesized that in DMD, epigenetic control may mediate the dysregulation of DD-miRNAs. To test the hypothesis that, in the muscular system, DD-miRNAs might be subjected to epigenetic control, we took advantage of the C2C12 myoblasts. Global epigenetic analysis was performed with the non-specific inhibitors of DNA methylation, (5-Azacytidine), and histone deacetylation (Givinostat and TSA) and confirmed this possibility. Gene expression analysis in the mdx diaphragm validated global changes in genes, which are involved in an epigenetic control. The analysis of epigenetic marks at IG-DMR and Meg3-DMR supported that the decreased expression of the

repressive H3K27me3 marker and the decreased DNA methylation level (of IG-DMR only) are the direct causes of DD-miRNAs upregulation in the dystrophic diaphragm.

**The DD-miRNA cluster regulates mitochondrial OxPhos in the dystrophic muscle.**

Rather than a hypothesis-driven approach, we undertook here a strategy of a non-supervised investigation, consisting of the *in vivo* co-overexpression of a 14 DD-miRNAs, and global transcriptomic bioinformatics analysis. This analysis pointed toward lipid metabolism and mitochondrial functions as the most dysregulated pathways downstream to the DD-miRNAs, supporting experimentally strongly that the mitochondrial OxPhos system is indeed the most affected pathway in the dystrophic muscle by the cooperative activity of the DD-miRNAs.

Since the activation of DD-miRNAs was also observed in the muscle and serum of three LGMD mouse models and during regeneration of normal muscle after Notexin-induced injury, the involvement of DD-miRNAs in mitochondrial functions might be associated with diverse situations of muscle injury and regeneration.

***In vivo* validation of control of mitochondrial OxPhos by DD-miRNAs.**

We wondered to what degree the dystrophic changes in the mdx muscle might be explained by the upregulation of DD-miRNAs. To answer this question, we overexpressed 14 DD-miRNAs *in vivo* in the muscle and compared transcriptomic, protein level, and mitochondrial activity of the mdx muscle to the DD-miRNA overexpressing C57Bl/6 muscle. We detected a high overlap between omics changes in the normal muscle overexpressing DD-miRNAs, and in the dystrophic muscle, naturally having elevated DD-miRNA levels. Of particular interest, the mitochondrial OxPhos, which is the highest bioinformatics-predicted target pathway for DD-miRNAs, was experimentally detected as the most downregulated pathway in both conditions.

This observation strongly supports that the DD-miRNAs are direct repressive mediators of OxPhos system in the dystrophic muscle. The upregulated DD-miRNAs are expected to downregulate target genes in the dystrophic muscle. As expected, therefore, we found a high-

level overlap in the downregulated transcripts (which are the direct targets of DD-miRNAs), in the normal muscle overexpressing DD-miRNAs, and in the dystrophic muscle. Surprisingly, a high overlap was found also in the upregulated transcripts, supporting that non-direct effects of DD-miRNAs may similarly occurs in the two systems. Taken together, the data support that DD-miRNAs upregulation plays important role in mediating omics changes and mitochondrial activity in the dystrophic muscle. The direct evaluation of the silencing of all DD-miRNAs in the mdx mouse was not possible, since the knocking out of the entire DD-miRNA cluster is embryonically lethal. We selected therefore an *in vitro* iPS-based strategy for the modeling of DD-miRNAs silencing in the muscle. The CRISPR-Cas9 induced deletion of the IG-DMR, led to a drastically reduced DD-miRNA expression in the *in vitro* differentiated skeletal myotubes derived from a human iPS cell line. The analysis of mitochondrial gene expression and activity in myotubes derived from two independent clones confirmed that DD-miRNA might control mitochondrial OxPhos in the muscular system. Thus, the present study linked DD-miRNAs with the control of mitochondrial activity in the regenerating myofiber.

DD-miRNAs are highly expressed in the quiescence muscle stem cell and down-regulated upon its activation<sup>13</sup> or in dystrophic satellite cells (**Figure 1E**), however the biological function of DD-miRNAs in muscle stem cells is yet unknown. Of note, it has recently been suggested that activation of the satellite cells in the exercised muscle is OxPhos-dependent<sup>28</sup>. It is tempting to speculate that by OxPhos inhibition DD-miRNAs are involved in the maintenance of stem cells quiescence in the resting muscle, whiles DD-miRNAs downregulation is required for the activation of stem cells in the exercising or regenerating muscle.

**Updated model for mitochondrial dysfunction in DMD.** It has been suggested long ago, that the entry of Ca<sup>2+</sup>, which is provoked in muscular dystrophy by sarcolemma instability, is followed by a pathological cascade that includes Ca<sup>2+</sup> impact on mitochondria, leading to myogenic degeneration<sup>29</sup>. This proposition for mitochondrial dysfunction in muscular

dystrophy is still widely accepted today<sup>30,31</sup>. We have recently demonstrated that increased miR-379 expression in the dystrophic muscle interferes with the OxPhos system and ATP production. Based on this discovery, we proposed a modified model for mitochondrial dysfunction in DMD. Our updated model for mitochondrial participation in the dystrophic cascade supports that in muscular dystrophy, not only miR-379, but also many other DD-miRNAs are coordinately upregulated and cooperatively affect mitochondrial functions in the dystrophic muscle.

In summary, the present investigation exposes a fundamental mechanism of mitochondrial adaptation in the dystrophic muscle and therefore opens a new perspective for therapeutic intervention.

**Author contributions.** AVH designed and performed experiments, analyzed results and wrote the paper. NB, PS, JP, KC, EG, EM, performed experiments and analyzed results. MS designed experiments and analyzed results. IR and DI designed experiments, analyzed results, managed the project and wrote the paper.

## Acknowledgment

The authors are Genopole's members, first French biocluster dedicated to genetic, biotechnologies and biotherapies. We are grateful to the “Imaging and Cytometry Core Facility” and to the *in vivo* evaluation, services of Genethon for technical support, to Ile-de-France Region, to Conseil Départemental de l’Essonne (ASTRE), INSERM and GIP Genopole, Evry for the purchase of the equipment. We are grateful to the Myobank, the tissue bank of the Association Française contre les Myopathies (AFM), and the Myology Institute (Paris, France) for providing DMD and healthy control skeletal muscle biopsies. This study was financially supported by the AFM; by the Institut National de la Santé et de la Recherche Médicale

(INSERM); the University Pierre et Marie Curie Paris 06; the Centre National de la Recherche Scientifique (CNRS).

**Competing interests:** All authors declare having no competing interests.

## 5 REFERENCES

1. Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. *Nat. Rev. Dis. Prim.* 2021;**7**.
2. Allen DG, Whitehead NP, Froehner SC. Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca<sup>2+</sup>, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy. *Physiol Rev* 2016;**96**:253–305.
3. Amor F, Vu Hong A, Corre G, Sanson M, Suel L, Blaie S *et al.* Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy. *J Cachexia Sarcopenia Muscle* 2021;**12**:677–693.
4. Jeanson-Leh L, Lameth J, Krimi S, Buisset J, Amor F, Le Guiner C *et al.* Serum Profiling Identifies Novel Muscle miRNA and Cardiomyopathy-Related miRNA Biomarkers in Golden Retriever Muscular Dystrophy Dogs and Duchenne Muscular Dystrophy Patients. *Am J Pathol* 2014;**184**:2885–98.
5. Sanson M, Hog Vu A, Massourides E, Bourg N, Suel L, Amor F *et al.* miR-379 links glucocorticoid treatment with mitochondrial response in Duchenne muscular dystrophy. *Sci Rep* 2020;**10**:9139.
6. da Rocha ST, Edwards CA, Ito M, Ogata T, Ferguson-Smith AC. Genomic imprinting at the mammalian Dlk1-Dio3 domain. *Trends Genet* 2008;**24**:306–16.
7. Ioannides Y, Lokulo-Sodipe K, Mackay DJG, Davies JH, Temple IK. Temple syndrome: Improving the recognition of an underdiagnosed chromosome 14 imprinting disorder: An analysis of 51 published cases. *J Med Genet* 2014;**51**:495–501.
8. Ogata T, Kagami M. Kagami-Ogata syndrome: A clinically recognizable upd(14)pat and related disorder affecting the chromosome 14q32.2 imprinted region. *J. Hum. Genet.* 2016;**61**:87–94.
9. Charlier C, Segers K, Wagenaar D, Karim L, Berghmans S, Jaillon O *et al.* Human-ovine comparative sequencing of a 250-kb imprinted domain encompassing the callipyge (clpg) locus and identification of six imprinted transcripts: DLK1, DAT, GTL2, PEG11, antiPEG11, and MEG8. *Genome Res.* 2001;**11**:850–862.
10. Pajak M. miRNAatp: miRNAatp: microRNA Targets - Aggregated Predictions. in miRNAatp: miRNAatp: microRNA Targets - Aggregated Predictions. <https://rdr.io/bioc/miRNAatp/man/miRNAatp.html>. Accessed 30 July 2021.
11. Seitz H, Royo H, Bortolin M-L, Lin S-P, Ferguson-Smith AC, Cavaillé J. A large imprinted microRNA gene cluster at the mouse Dlk1-Gtl2 domain. *Genome Res* 2004;**14**:1741–8.
12. Gao Y-Q, Chen X, Wang P, Lu L, Zhao W, Chen C *et al.* Regulation of DLK1 by the maternally expressed miR-379/miR-544 cluster may underlie callipyge polar overdominance inheritance. *Proc Natl Acad Sci U S A* 2015;**112**:13627–32.
13. Castel D, Baghdadi MB, Mella S, Gayraud-Morel B, Marty V, Cavaillé J *et al.* Small-RNA sequencing identifies dynamic microRNA deregulation during skeletal muscle lineage progression. *Sci Rep* 2018;**8**:4208.

14. Kagami M, O'Sullivan MJ, Green AJ, Watabe Y, Arisaka O, Masawa N *et al.* The IG-DMR and the MEG3-DMR at human chromosome 14q32.2: Hierarchical interaction and distinct functional properties as imprinting control centers. *PLoS Genet* 2010;**6**:1–13.
15. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database Hallmark Gene Set Collection. *Cell Syst* 2015;**1**:417–425.
16. Wang Y, Luo J, Zhang H, Lu J. microRNAs in the Same Clusters Evolve to Coordinately Regulate Functionally Related Genes. *Mol Biol Evol* 2016;**33**:2232–2247.
17. Calvo SE, Clauser KR, Mootha VK. MitoCarta2.0: An updated inventory of mammalian mitochondrial proteins. *Nucleic Acids Res* 2016;**44**:D1251–D1257.
18. Pescatori M, Broccolini A, Minetti C, Bertini E, Bruno C, D'Amico A *et al.* Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. *Faseb J* 2007;**21**:1210–1226.
19. Spinazzi M, Casarin A, Pertegato V, Salviati L, Angelini C. Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. *Nat Protoc* 2012;**7**:1235–1246.
20. Massouridès E, Polentes J, Mangeot PE, Mournetas V, Nectoux J, Deburgrave N *et al.* Dp412e: A novel human embryonic dystrophin isoform induced by BMP4 in early differentiated cells. *Skelet Muscle* 2015;**5**:40.
21. Das PP, Hendrix DA, Apostolou E, Buchner AH, Canver MC, Beyaz S *et al.* PRC2 Is Required to Maintain Expression of the Maternal Gtl2-Rian-Mirg Locus by Preventing De Novo DNA Methylation in Mouse Embryonic Stem Cells. *Cell Rep* 2015;**12**:1456–1470.
22. Carr MS, Yevtodiyenko A, Schmidt CL, Schmidt J V. Allele-specific histone modifications regulate expression of the Dlk1-Gtl2 imprinted domain. *Genomics* 2007;**89**:280–290.
23. Dai R, Lu R, Ahmed SA. The Upregulation of Genomic Imprinted DLK1-Dio3 miRNAs in Murine Lupus Is Associated with Global DNA Hypomethylation. *PLoS One* 2016;**11**:e0153509.
24. Molina-Pinelo S, Salinas A, Moreno-Mata N, Ferrer I, Suarez R, Andrés-León E *et al.* Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer. *Oncotarget* 2018;**9**:4395–4410.
25. Kameswaran V, Bramswig NC, McKenna LB, Penn M, Schug J, Hand NJ *et al.* Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets. *Cell Metab* 2014;**19**:135–45.
26. Rugowska A, Starosta A, Konieczny P. Epigenetic modifications in muscle regeneration and progression of Duchenne muscular dystrophy. *Clin. Epigenetics*. 2021;**13**:1–25.
27. Consalvi S, Sandoña M, Saccone V. Epigenetic reprogramming of muscle progenitors: Inspiration for clinical therapies. *Stem Cells Int*. 2016;**2016**.
28. Abreu P, Kowaltowski AJ. Satellite cell self-renewal in endurance exercise is mediated by inhibition of mitochondrial oxygen consumption. *J Cachexia Sarcopenia Muscle* 2020;**11**:1661–1676.
29. Wrogemann K, Pena SD. Mitochondrial calcium overload: A general mechanism for cell-necrosis in muscle diseases. *Lancet (London, England)* 1976;**1**:672–4.
30. Mareedu S, Million ED, Duan D, Babu GJ. Abnormal Calcium Handling in Duchenne Muscular Dystrophy: Mechanisms and Potential Therapies. *Front Physiol* 2021;**12**:647010.
31. Zulian A, Schiavone M, Giorgio V, Bernardi P. Forty years later: Mitochondria as therapeutic targets in muscle diseases. *Pharmacol. Res.* 2016;**113**:563–573.



**Figure 1**







Figure 2




5

10

15

**Figure 3**



**Figure 4**






Figure 5





**Figure 7**



## Figure legends

### Figure 1: Characterization of DD-miRNAs dysregulation in the regenerating muscle.

**A.** Relative expression levels of DD-miRNAs in muscle biopsies of DMD patients compared to healthy controls (n=4). **B.** Relative expression levels of DD-miRNAs in diaphragm muscle of mdx mouse model compared to C57Bl10 control (n=6). **C-D.** Relative expression levels of DD-miRNAs in the serum (C) and muscle (D) of 3 LGMD mouse models compared to C57Bl6 control (n=4). **E.** Heatmap presenting expression level of DD-miRNAs, other transcripts of the Dlk1-Dio3 locus, and myogenic transcription factors during *in vivo* acute muscle regeneration (n=2-3). The relative expression level is illustrated by column Z-scores, colored from blue to red, indicating from lowest to highest expression. **F.** ISH of miR-127-3p (upper panels) and miR-379-5p (lower panels) in diaphragm of mdx and controls. Nucleus was colored in pink while miRNAs of interest was colored in dark blue. Scramble probes served as negative control. Scale bar: 100  $\mu$ m. **G.** Relative expression of three DD-miRNAs through *in vitro* differentiation of satellite cells from muscles of 5-week-old mdx and C57Bl10 control mice (n=3). QSC: quiescent satellite cells; ASC: activated satellite cells; D2/D5-Diff: Day 2/5 differentiated myotubes. IM: intramuscular injection. Data in all graphical presentations are presented as mean $\pm$ SEM. Statistics were performed with Student t-test. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.

### Figure 2: DD-miRNAs expression is epigenetically controlled in DMD.

**A.** DNA methylation levels of 29 CpGs in IG-DMR and 8 CpGs in Meg3-DMR. **B.** ChIP-qPCR of H3K27me3, H3K4me3, and H3K9ac in IG-DMR and Meg3-DMR. The PCR amplicons are shown schematically in **Supplemental Figure 2E**. Statistics were performed by 2-way ANOVA test. Data are presented as mean $\pm$ SEM. All experiments were performed in the diaphragms of 5-week-old mdx and C57Bl10 controls.\*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.

### Figure 3: Selection of DD-miRNAs and their *in vivo* overexpression by AAV vectors

**A.** Of the selected 14 DD-miRNAs, 13 are commonly dysregulated in the serum of DMD patients and GRMD dog models <sup>3,4</sup>, in the diaphragm muscle of the mdx mouse (GEO accession: GSE3625 **B.** AAV construction strategy for the overexpression of 14 DD-miRNAs. **C.** Experimental design of the *in vivo* overexpression of DD-miRNAs by the intramuscular co-

injection of 5 AAV vectors to the TA muscle of a wild-type 4-week-old mouse (miRs). Injection of AAV vector with same expression cassette but pre-miRNAs sequences at the same titer (Emp) served as control in the experiment. **D.** Masses of TA muscles 1-month and 3-month post-injection (n=10). **E-H.** *In situ* max tetanic (**E**) and max twitch (**G**) forces of treated muscles 3-month post-injection (n=5), and its normalization to muscle masses (**F, H**). Data are presented as mean±SEM. Statistics were performed with Student t-test. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.

#### **Figure 4: Comparison of the transcriptomic profiles between 14 DD-miRNAs ectopic expression and the mdx dystrophic muscle**

**A.** Venn diagram of dysregulated genes in mdx diaphragm compared to wild-type control and in DD-miRNAs-overexpressed TA muscle compared to AAV control. **B.** Dot plot of log2 fold change values of 1520 commonly dysregulated genes in the 2 transcriptomes and its Pearson correlation test. Cyan dots represent mitochondrial-related genes (Mitocarta 2.0). **C, D.** Volcano plots of mdx/WT transcriptome (**C**) and miRs/Emp transcriptome (**D**). Blue dots represent significantly down-regulated genes with fold change of mdx versus WT less than -2 while red dots represent significantly up-regulated genes with fold change of mdx versus WT greater than 2 (BH-adjusted p-value < 0.05). **E, F.** Volcano plots of all Hallmark and Gene Ontology (Biological Process) gene sets from GSEA analysis, comparison of mdx/WT transcriptome (**E**) and miRs/Emp transcriptome (**F**). Blue dots represent significantly down-regulated pathways in mdx compared to WT while red dots represent significantly up-regulated pathways in mdx compared to WT (BH-adjusted p-value < 0.05).

#### **Figure 5: DD- miRNAs are predicted to target metabolic pathways in the skeletal muscle.**

**A.** Venn diagram of significantly down-regulated genes in mdx/WT, of miRs/Emp transcriptome and of DD-miRNAs's predicted target genes. **B.** Pathway analysis of the 269 predicted targets for DD-miRNAs identified in **A**. **C-D.** Validation at RNA (**C**) and protein (**D**) levels of selected predicted targets (n=4). Data in **C** and **D** are presented as mean±SEM. Statistics were performed with Student t-test. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.



## Figure 6: DD-miRNAs modulate mitochondrial metabolism in the dystrophic muscle.

**A, D.** Levels of mitochondrial DNA in mdx versus WT diaphragm muscles (**A**, n=6) and miRs versus Emp TA muscles (**D**, n=4). **B, E.** Citrate Synthase activities in mdx versus WT diaphragm muscles (**B**, n=6) and miRs versus Emp TA muscles (**E**, n=6). **C, F.** ATP concentration in mdx versus WT diaphragm muscles (**C**, n=6) and miRs versus Emp TA muscles (**F**, n=6). **G, H.** Staining of COX (upper panels) and SDH (low panels) activities in mdx versus WT diaphragm muscles (**G**) and miRs versus Emp TA muscles (**H**). **I.** Western blots of five representative proteins for five OxPhos complexes comparing mdx versus WT diaphragm muscles and miRs versus Emp TA muscles (n=4), and their quantification (right). **K, L.** Activities of different OxPhos enzymes comparing mdx versus WT diaphragm muscles (**K**, n=5-6) and miRs versus Emp TA muscles (**L**, n=6). Data are presented as mean±SEM. Statistics were performed with Student t-test. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.

## Figure 7: Knocking down DD-miRNAs results in increased OxPhos expression and activity.

**A.** Diagram of IG-DMR deletion by CRISPR-Cas9. **B-D.** Analysis of DD-miRNAs knocked-down iPS clones compared to control (2 iPS clones, n=4). (**B**), RNA level of selected transcripts of five OxPhos complexes and predicted DD-miRNA targets; (**C**), Western blot of five representative proteins for five OxPhos complexes. (**D**), CS-normalized activity of five OxPhos complexes. Data in **B-D** are presented as mean±SEM. Statistics were performed with Student t-test. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.

# **Dlk1-Dio3 cluster miRNAs regulate mitochondrial functions in the dystrophic muscle in Duchenne Muscular Dystrophy**

5    Ai Vu Hong <sup>1,2</sup>, Nathalie Bourg <sup>1,2</sup>, Peggy Sanatine <sup>1,2</sup>, Jerome Poupiot <sup>1,2</sup>, Karine Charton <sup>1,2\*</sup>,  
 Evelyne Gicquel <sup>1,2</sup>, Emmanuelle Massourides<sup>3</sup>, Marco Spinazzi <sup>4,5</sup>, Isabelle Richard <sup>1,2</sup> and  
 David Israeli <sup>1,2</sup>


10

## **Supplemental material**

## Supplemental Figure 1: DD-miRNAs expression level in different organs, tissues and skeletal muscle cellular subpopulations.

**A.** Comparison of expression levels of 2 representatives DD-miRNAs (miR-431-5p and miR-495-3p) between different organs from 5-week-old wild-type and mdx mice (n=3-4). **B.**


Comparison of expression levels of 4 representative DD-miRNAs between different FACS-sorted cell populations from 5-week-old mdx mice and its healthy controls (n=3). Muscle mono-nucleated cells (MMNC) fractions were FACS-sorted by using CD31, CD45, Sca1 and Vcam1 markers from hind limb muscles of mdx and control mice. We quantified the expression of four representative DD-miRNAs (n=3) in five subpopulations that are typically found in skeletal muscle, which are the hematopoietic cells (CD45+), endothelial cells (CD31+), fibro-adipocyte progenitors (FAPs) (CD31-/CD45-/Sca1+), satellite cells (CD31-/CD45-/Sca1-/Vcam1+), and cells that are negative for all four markers (CD45-/CD31-/Sca1-/Vcam1-). Expression of DD-miRNAs was detected in FAPs, satellite cells, and CD31/CD45/Sca1/Vcam1 negative cellular fraction. Comparison between the mdx and WT cells showed that DD-miRNAs were expressed to similar levels in the FAPs and in the negative cell population. In contrast, a lower DD-miRNAs expression was detected in satellite cells derived from the mdx mouse compared to control, which is consistent with the activated state of satellite cells of the mdx mouse, and with the fact that DD-miRNAs are known to be downregulated in activated satellite cells<sup>1</sup>. Data are presented as mean±SEM. \*P<0.05; \*\*P<0.01; \*\*\*P<0.001.



**Supplemental Figure 2: Epigenetic drugs affect the expression of Dlk1-Dio3 transcripts in myogenic cells.**


Relative expression of maternal and paternal Dlk1-Dio3 transcripts in C2C12 cells treated by Givinostat (A), Trichostatin A (B), and 5-azacytidine (C) compared to DMSO control (n=4).

**D.** Illustration of the PCR amplicons in **Figure 2A-B** in the context of the DLK1-Dio3 locus. TSA, Trichostatin A; 5-Aza, 5-azacytidine; BS-PCR, PCR from bisulfite-converted DNA; ChIP, Chromatin Immuno-Precipitation. Data are presented as mean±SEM. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.




### Supplemental Figure 3: Selection and *in vivo* overexpression of 14 DD-miRNAs in skeletal muscle.

**A.** Volcano plot of miRNA profiling of the diaphragm of 8-week-old mdx and control mice (upper part), and a zoom-in of significantly up-regulated miRNAs in mdx muscle (lower part) (data was taken and reanalyzed from GEO: GSE36257<sup>2</sup>). Expression levels are presented by the size of the circle. DD-miRNAs are colored (pink or red). MiRNAs in red were selected for the overexpression by AAV vectors in the present study. **B.** Validation of DD-miRNAs overexpression in the treated mice. TA muscles were analyzed one month after injection with AAV-DD-miRNAs (miRs) compared to AAV-Empty control (Emp) (n=6). **C.** Comparison of DD-miRNAs overexpression in different systems: muscle biopsies from DMD patients compared to healthy controls (**Figure 1A**), diaphragm muscle of mdx mice compared to C57Bl10 control (**Figure 1B**), and DD-miRNAs overexpression in the TA muscle of a healthy mouse by AAV vectors. Data in **B-C** are presented as mean±SEM.




## Supplemental Figure 4: DD-miRNAs affect mitochondrial functions in the dystrophic muscle

**A.** Venn diagram of mitochondria-related genes (Mitocarta 2.0) and of significantly dysregulated genes, in mdx/WT and miRs/Emp transcriptomes. **B-C.** GSEA analysis of OxPhos gene set comparing mdx versus WT diaphragms (**A**) and miRs versus Emp TA muscles (**B**). **D-G.** Expression level of Meg3 transcript and GSEA analysis of OxPhos gene set in muscle biopsies of DMD patients compared to healthy controls in two different datasets. Data was taken and reanalyzed from GEO GSE6011<sup>3</sup> (**D-E**) and GEO GSE38417 (**F-G**). Data are presented as mean±SD. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.



## Supplemental Figure 5: Biallelic deletion of IG-DMR in hiPSCs.

**A.** Confirmation of 11-kb IG-DMR deletion in different IG-DMR<sup>-/-</sup> clones by PCR using different sets of primers (left). Positions of primers used in PCR are illustrated (right). **B.** Diagram of myogenic differentiation methods for hiPSCs. **C.** Representative images of D17 myoblasts (upper panels) and D20 myotubes (lower panels) of different IG-DMR<sup>-/-</sup> and control clones. **D-E.** Relative expression levels of representative DD-miRNAs at D0 (**D** - hiPSCs) and D20 (**E** - myotubes) in 2 IG-DMR<sup>-/-</sup> clones compared to control (n=4). Data are presented as mean±SEM.





# Supplemental Tables

## Supplemental Table 1: List of primers, antibodies, reagents, R packages, and public databases used in the present study.

### Bisulfite PCR primers (mmu)

Targets	Forward	Reverse
IG-DMR	TGTGTTGTGGATTTAGTTGTAGTTTA	TAATCCCATTCCCAATCTATAAAAATA
Meg3-DMR	AAATTTTGTAAAGGAAAAGAATTTTATAGG	TTCAAAATTACTAATCAACATAAACCTC

### ChIP PCR primers (mmu)

Targets	Forward	Reverse
IG-DMR_R1	GCCTCGCGGCCTGTCTACG	CGGTAAACCCACATACGTGTGCCA
IG-DMR_R2	TGCCAGAGCAGTGCTACACGA	CAGCCTGGGTCCACAGCACA
IG-DMR_R3	GCGCTGCAGCCGCTATGCTA	CAGCACCGGAGAGGACAGCC
IG-DMR_R4	TCAGCCACAGTTCCAGGCA	GCCTGTTTTGGGGGAGCTT
IG-DMR_R5	CCTTGGCATCCTGGCTACCG	CCCGGGGCTCAGGAGTAGGG
IG-DMR_R6	CGCAGGTCCTAACACGGCAC	GAGCGTTGGAGCCTTGAGCC
IG-DMR_R7	GGCTCAAGGCTCCAACGCTC	TGAAGACCCCTGGCGAGCAA
Meg3-DMR_R1	CATGTTGCCCCCTTTGCCACTTAG	CCCAGCAACCCGGAGTGTACTGTG
Meg3-DMR_R2	AAGCATTACCACAGGGACCCATT	CCCAAATGTTAGCCTGGAGGCTGT
Meg3-DMR_R3	CAAGATAGTCCGTCAGAATCGGGG	GGGCGATTTGTAGACAGAACTGG
Meg3-DMR_R4	ACCTTTATCCTTGGTGCCTGAGA	GCATTCTGCTGCAATGCGCTCATT
Meg3-DMR_R5	TGGGTGCGGCTACAGCAATTTGTC	ATGTCGTCTTCATTTTTGCACATC
Meg3-DMR_R6	GCGCCACAGAAGAATCTCTTACC	TTAATCAGGGTCTCTACCGCGCTG
Meg3-DMR_R7	GGGTCCGGTCCACTAGGGCTTTTT	CCCACGTTCCGCCGAGAACCTGGC

### qPCR-miRNAs primers

miRNA	Supplier	Reference
miR-433-3p	Thermo Fisher	001028
miR-127-3p	Thermo Fisher	000452
miR-379-5p	Thermo Fisher	001138
miR-411-5p	Thermo Fisher	001610
miR-494-3p	Thermo Fisher	002365
miR-543-3p	Thermo Fisher	001298
miR-495-3p	Thermo Fisher	001663
miR-381-3p	Thermo Fisher	000571
miR-487b-3p	Thermo Fisher	001285
miR-431-5p	Thermo Fisher	001979
miR-134-5p	Thermo Fisher	001186
miR-370-3p	Thermo Fisher	002275
miR-299a-5p	Thermo Fisher	000600
miR-541-5p	Thermo Fisher	002562
miR-409-3p	Thermo Fisher	002332
miR-410-3p	Thermo Fisher	001274
miR-337-5p	Thermo Fisher	002515
U6	Thermo Fisher	001973
miR-93-5p	Thermo Fisher	001090



#### qPCR-GE primers (mmu) SYBR

Targets	Forward	Reverse
Meg3	TTGCACATTTCTGTGGGAC	AAGCACCATGAGCCACTAGG
Rian	CGTGTGTGTGTGTGTGGT	GCCAAGGTCTCTACCAGCAG
Mirg	GGCAAGGTCTAGGATGGACA	CGCCAGCTTCTGAATACTCC
Dlk1	GACCTGGAGAAAGGCCAGTA	AGGGAGAACCATTGATCACG
Sar1b	TTCCTTGGATTGGATAATGCCG	GCCAGCAATAGTAAGCTCTTCTG
Bnip3	TCCTGGGTAGAACTGCACTTC	GCTGGGCATCCAACAGTATTT
Hsd17b4	AGGGGACTTCAAGGGAATTGG	GCCTGCTTCAACTGAATCGTAA
Cycs	CCAAATCTCCACGGTCTGTTC	ATCAGGGTATCCTCTCCCCAG
Pex19	GACAGCGAGGCTACTCAGAG	GCCCCAGAGATTGAGAGCA
Uqc	TTGCTGGTGCGAGTCTTAG	GTGTCCGCTCCAACAGTCT
Timm44	CTAGGCAGCGGAATCCAATTT	GCAAGCCTGACAAAAACCTTT
Ndufs1	AGGATATGTTCCGACAACCTGG	TCATGGTAACAGAATCGAGGGA
Cs	GGACAATTTTCCAACCAATCTGC	TCGGTTTATTCCCTCTGCATA
Gpd2	GAAGGGGACTATTCTGTGGGT	GGATGTCAAATTCGGGTGTGT
Slc25a20	GACGAGCCGAAACCCATCAG	AGTCGGACCTTGACCGTGT
Rplp0	CTCCAAGCAGATGCAGCAGA	ATAGCCTTGCGCATCATGGT

#### qPCR-GE primers (hsa)

Targets	Forward	Reverse
Ndufs1	TTAGCAAATCACCCATTGGACTG	CCCCTCTAAAAATCGGCTCCTA
Ndufv1	AGGATGAAGACCGGATTTTAC	CAGTCACCTCGACTCAGGGA
Ndufb4	ATGTCGTTCCCAAAGTATAAGCC	GAAGCAGGTACTCTCGTTTCAG
Ndufa9	GTCACGTTCTGCCATTACTGC	GGTGGTTGACAACATATCGCC
Ndufb2	GGAGGCCGCCTTTTCAGAA	GGAAGGATCAGGATACGGAAAGT
Ndufb11	CGTCCGCTGGGAATCTAGC	ACGGGGTCTTGTCTATAACCA
Ndufs2	GTCCGATTGCCGATTACAGC	GCTTGGGTACATAACAGCTCC
Mt-ND1	CCACCTCTAGCCTAGCCGTTTA	GGGTCATGATGGCAGAGTAAT
Mt-ND6	CAAACAATGTTCAACCAGTAACCACTAC	ATATACTACAGCGATGGCTATTGAGGA
Sdha	CAAACAGGAACCCGAGGTTTT	CAGCTTGGTAACACATGCTGTAT
Shdb	ACAGCTCCCCGTATCAAGAAA	GCATGATCTTCGGAAGGTCAA
Sdhc	GAGAAGCTCCAGAGCCTTTTAAAGA	CAACTCCCAGTCCCCTGAAG
Sdhd	ATTTCTTCAGGACCGACCTATCC	CAGCCTTGAGCCAGAATG
Uqcrls1	CTGAATACCGCCGCTTGAA	ATGCGACACCCACAGTAGTTA
Uqcrls1	GGGGCACAAGTGCTATTGC	GTTGTCCAGCAGGCTAACC
Uqcrls1	GGTAAGCAGGCGGTTTCAG	AGGTCCAGTGCCCTCTTAATG
Uqcrls1	CGCGAGTTTGGGAATCTGAC	TAGTGAAGACGTGCGGATAGG
Uqcrls2	TTCAGCAATTTAGGAACCAACC	GGTCACACTTAATTTGCCACCA
Mt-CYB	ATCACTCGAGACGTAATATGGCT	TGAACTAGGTCTGTCCCAATGTATG
Cox7b	CTTGGTCAAAGCGCACTAAATC	AAAATCAGGTGTACGTTTCTGGT
Cox5a	ATCCAGTCAGTTCGCTGCTAT	CCAGGCATCTATATCTGGCTTG
Cox4l1	GAGAAAGTCGAGTTGTATCGCA	GCTTCTGCCACATGATAACGA
Cox6a1	AGTTGGTGTGCTCCTCGGTTTC	GTGAGAGTCTTCCACATGCGA
Cox7a1	CCGCTTTTCAAGACCGAGTG	CCCTTCAGGTACAACGGGA
Mt-COI	GACGTAGACACACGAGCATATTTCA	AGGACATAGTGAAGTGAGCTACAAC
Atp5f1	AGGTCCAGGGGTATTGCAG	TCCTCAGGGATCAGTCCATAAC
Atp5e	GTGGCCTACTGGAGACAGG	GGAGTATCGGATGTAGCTGAGT
Atp5a1	GTATTGCCCGCTACATGG	AGGACATACCCTTTAAGCCTGA
Atp5b	CCTGTCAGGGACTATGCGG	TCCTTACTGTGCTCTCACCCA
Atp5c1	TCACCAGGAGACTAAAGTCCATC	TATTTTGTGCTGCCGCTACCAT
Mt-ATP6	TAGCCATACACAACACTAAAGACGA	GGGCATTTTAAATCTTAGAGCGAAA
Gpd2	GGCAGTGAAAGGGACGATTCT	GCTGCTTAAACATAGGCCAGGT
Bnip3	CAGGGCTCCTGGGTAGAACT	CTACTCCGTCCAGACTCATGC
Slc25a20	GACCAGCCAAAACCCATCAG	AGAGGGTGACCGACGAACA
Sar1b	TACAGTGGTTTCAGCAGTGTG	AGTGGGATGTAATGTTGGGACA
Acta1	GGCATTACGAGACCACTAC	CGACATGACGTTGTTGGCATAC
Tfam	ATGGCGTTTCTCCGAAGCAT	TCCGCCCTATAAGCATCTTGA
Ppargc1a	TCTGAGTCTGTATGGAGTGACAT	CCAAGTCGTTACATCTAGTTCA

#### qPCR-GE primers (mmu) Taqman

Targets	Supplier	Reference
Rtl1	Thermo Fisher	mm02392620_s1
Myod1	Thermo Fisher	mm00440387_m1
Myog	Thermo Fisher	mm00446195_g1
Des	Thermo Fisher	hs00157258_m1
Myh1	Thermo Fisher	mm01332489_m1
Myh2	Thermo Fisher	mm01332564_m1
Myh4	Thermo Fisher	mm01332541_m1
Myh7	Thermo Fisher	mm01319006_g1
Eif4g2	Thermo Fisher	hs00154952_m1
Usmg5	Thermo Fisher	hs00910071_g1

#### Other qPCR primers

Targets	Forward	Reverse
mitoDNA(mmu)	CTAGAAACCCCGAAACCAAA	CCAGCTATCACCAAGCTCGT
gDNA (mmu)	ATGGGAAGCCGAACATACTG	CAGTCTCAGTGGGGGTGAAT
AAV DNA	AGTCCGCCCTGAGCAAAGA	GCTGGAGTTCGTGACCGC

#### Primers for screening IG-KO clones

Primers	Sequences
F1	GGTGAGCTTGCATTCAAAGG
R1	GAATGCAATGGTCTGTGGCT
F2	CTACACTCACCTAGCCTCC
R2	CGAGAGTCTGGCCTTATGTAC

#### Antibodies Western Blot

Protein	Supplier	Reference	Dilution
H3K4me3	Abcam	ab8580	1/1000
H3K9me3	Abcam	ab8898	1/700
H3K36me3	Active Motif	61102	1/1000
H3K79me2	Milipore	04-835	1/2000
H3K27me3	Milipore	07-449	1/1000
H4K16ac	Active Motif	39929	1/500
H3K9ac	Active Motif	39918	1/500
H3	Abcam	ab1791	1/1000
Dnmt3a	Novusbio	64B1446	1/500
TET2	ProteinTech	21207-1-AP	1/500
ACTIN	Sigma	A2066	1/250
SLC25A20	Abcam	ab82678	1/500
BNIP3	Abcam	ab10433	1/500
SAR1b	Abcam	ab155278	1/1000
NDUFA9	Abcam	ab14713	1/1000
SDHA	Abcam	ab14715	1/2000
UQCRC2	Abcam	ab14745	1/1000
MT-COI	Abcam	ab14705	1/1000
COXIV	Abcam	ab64885	1/500
ATP5A	Abcam	ab14748	1/1000

#### Antibodies FACS

Target	Supplier	Reference	Dilution
IgG2a/k-APC	BD Biosciences	553932	1/50
IgG2b/k-APC	BD Biosciences	553991	1/50
IgG2a/k-PE	BD Biosciences	553930	1/50
IgG2a/k-Biotin	BD Biosciences	553928	1/50
CD31-APC	BD Biosciences	551262	1/50
CD45-APC	BD Biosciences	559864	1/50
Sca1-PE	BD Biosciences	553108	1/50
VCAM1-Biotin	BD Biosciences	553331	1/50
Streptavidin-PE.Cy7	BD Biosciences	557598	1/400
FcBlock	BD Biosciences	553142	1/300
7AAD	Sigma	A9400-1MG	1/300

#### ISH Probe

miRNA	Supplier	Sequence (5'-3')	Reference
mmu-miR-127-3p	Qiagen	AGCCAAGCTCAGACGGATCC	YD00615633
hsa-miR-379-5p	Qiagen	CCTACGTTCCATAGTCTACCA	YD00617025
Scramble probe	Qiagen	GTGTAACACGTCTATACGCCCA	163039916

#### R packages used in the study

Package	Reference
DESeq2	4
ReactomePA	5
biomaRt	6
msigdb	7
miRNAatp	8

#### Public database used in the study

Identifier	Detail
GSE36257	miRNA microarray in diaphragm muscle of mdx and WT mice
E-MTAB-5955	miRNA sequencing in quiescent and activated satellite cells from WT mice
GSE64379	RNA-sequencing of quiescent and activated satellite cells from WT mice
GSE47362	ChIP-seq of quiescent and activated satellite cells from WT mice
GSE6011	Microarray of muscle biopsies from young DMD patients and age-matched healthy controls
GSE38417	Microarray of muscle biopsies from young DMD patients and age-matched healthy controls

## Supplemental Table 2: List of sgRNAs used in the present study.

Selection of sgRNAs were done by GPP sgRNA Designer <sup>9</sup>. Number of off-targets (MM0-3) were further identified by CHOPCHOP <sup>10</sup>. MM0, -1, -2, -3: number of off-targets with 0, 1, 2, 3 mismatches, respectively.

sgRNA	sgRNA sequences	Target sequences	MM0	MM1	MM2	MM3
sglGKO_5end	GAACCCAACUGUGUGUGACA	GAACCCAACCTGTGTGTGACAGGG	1	0	0	12
sglGKO_3end	GCAUUGAAUGUAUGGCCACG	GCATTGAATGTATGGCCACGTGG	1	0	0	1

5

## Supplemental Table 3: List of off-targets associated with sgRNAs used in this study.

Off-targets were identified by CHOPCHOP <sup>10</sup>. Mismatches of off-target sequences are colored in red.

10

sgRNA	Location (hg38/GRCh38)	Number of mismatches	Sequence (including mismatches)
sglGKO_5end	chr1:1326161	3	aAACCCatCTGTGTGgGACATGG
sglGKO_5end	chr1:110269095	3	GAACCCatCaGTcTGTGACAGGG
sglGKO_5end	chr10:48837462	3	GAgCCaAACTGTGgGTGACAGGG
sglGKO_5end	chr10:73645297	3	CCCTcTCACACAcgGTTGGtTTC
sglGKO_5end	chr10:131522611	3	CCTTGTCcCACACAGaTaGGTTC
sglGKO_5end	chr11:17401675	3	GAgCCCAACTtTGTGTGtCAGGG
sglGKO_5end	chr12:16319475	3	aAACCCAACCTGTGTGTtACcTGG
sglGKO_5end	chr2:132513114	3	CCGTGTgACACAtgGTTGGGTTTC
sglGKO_5end	chr20:60305293	3	CCTTGcaACACACAGTTtGGTTC
sglGKO_5end	chr5:123613302	3	CCCTGTCACACAgAcTgGGGTTTC
sglGKO_5end	chr6:90122061	3	GAACCCtACcaTGTGTGACAAGG
sglGKO_5end	chr8:11759288	3	CCGTGTCACACAtAGagGGGTTTC
sglGKO_3end	chr1:54241432	3	CCACGTGGCtAgACATgCAATGC

**Supplemental Table 4: Selection of DD-miRNAs for overexpression in muscle.** Fourteen miRNAs were selected to be overexpressed in the TA muscle of the WT mouse. The choice of miRNAs was based on their expression and dysregulation levels in dystrophic serum, skeletal muscle and quiescent satellite cells. Overexpression data is provided in the excel file

5 **“Supplemental Table 4”**

**Supplemental Table 5: Gene Set Enrichment Analysis of transcriptomes from dystrophic muscle and DD-miRNAs overexpressed muscles.** The data is provided in the Excel file **“Supplemental Table 5”**

10 **Supplemental Table 6: List of bioinformatics predicted target genes for the selected 14 DD-miRNAs.** Five prediction tools (DIANA, Targetscan, PicTar, Miranda, and miRDB) were used, generating 5295 candidate targets predicted by at least two different tools. This list of 5295 candidates was crossed with experimental data of transcripts that are downregulated in the injected TA muscle and in the mdx diaphragm. The analysis resulted in 269 DD-miRNAs predicted targets, which is provided in the Excel file **“Supplemental Table 6”**

15

## Extended materials and methods

### Muscle biopsies

Human skeletal muscle tissues were obtained from Myobank, the tissue bank of the Association Francaise contre les Myopathies (AFM; <https://www.institut-myologie.org/en/recherche-2/myobank-afm/>). Open skeletal muscle biopsies were performed after informed consent, according to the Declaration of Helsinki. Muscle biopsies included in this study were derived from paravertebral (two controls and two DMD), gluteus, and tensor fasciae latae (one each control and one DMD) muscles. Details of patients and the biopsies are presented in **Table 1**.

**Table 1: Human muscle biopsies used in the present study**

Group	age (years)	Muscle	DMD mutation
DMD	8	Tensor fasciae latae	non specify
	11	Gluteus	Deletion Exon 3-37
	15	Paravertebral	Deletion Exon 10-11
	15	Paravertebral	Deletion Exon 50-52
Healthy	14	Paravertebral	None
	14	Paravertebral	
	15	Gluteus	
	19	Tensor fasciae latae	

### AAV construction and production

The 14 pre-miRNA sequences were obtained from UCSC website (<https://genome-euro.ucsc.edu/>), spanning 100 nucleotides before and after the mature miRNA sequences. The selected pre-miRNA sequences were then arranged consecutively which respect the genomic sequences of the miRNAs. Two or three pre-miRNAs were used per AAV construct. The constructed sequences were then synthesized (Genewiz) and subcloned into a donor plasmid (AAV-CMV-eGFP) by classical molecular biology technique. AAV9 viral vectors production was performed as already described<sup>11</sup>. Titration was performed by qRT-PCR using primers corresponding to the sequences of AAV ITR or eGFP. Sequences of PCR primers can be found in **Supplemental Table 1**.

## Satellite cell isolation from skeletal muscles and their *in vitro* differentiation

Satellite cells were isolated from limb muscles as described<sup>12</sup>, with some small modifications.

All hind limb muscles of 5-weeks old mice were collected and minced by using scissors. The samples were then put in the digestion medium of DMEM with 3U/ml Dispase II (Thermo

Fisher Scientific), 0.5 U/ml Collagenase A (Sigma), 0.2% BSA (Sigma), and 1X Pen-Strep (Thermo Fisher Scientific) for two hours at 37°C with gentle shaking. The lysates were then

passed through successive strainers (100, 70, and 40 µm) to eliminate fibers and debris.

Subsequently, red blood cells were removed from the samples by Versalyse (Beckman Coulter, Reference A09777). The mono-nucleated cells were then blocked by Mouse BD Fc Block (BD

Pharmingen, Reference 553142), stained with CD31-APC, CD45-APC, Sca1-PE, Vcam1-PE.Cy7 and viability marker 7AAD. The corresponding isotype controls were used in parallel

to determine the non-specific binding of antibodies. Details of antibody panel used in FACS sorting are presented in **Supplemental Table 1**. The cells were then FACS-sorted by Astrios

Cell Sorter (Beckman Coulter). Satellite cells, marked as CD31<sup>-</sup> CD45<sup>-</sup> Sca1<sup>-</sup> Vcam1<sup>+</sup>, were

directly placed in the proliferating medium containing Ham's F-10 (Hyclone) supplemented with 10% horse serum and 2.5 ng/ml bFGF (PeproTech, Reference 100-18B), and incubated at

37°C, 5% CO<sub>2</sub> for 3 days. Proliferated cells were then switched into a differentiation medium containing DMEM and 5% Horse Serum (Gibco) and kept at 37°C, 5% CO<sub>2</sub> for 5 days.

## Bisulfite Conversion and DNA methylation analysis

Genomic DNA of muscle tissues was extracted by Phenol:Chloroform:Isoamyl Alcohol standard protocol. Purified DNA was then treated with sodium bisulfite by using EpiTech

Bisulfite Kit (Qiagen, Reference 59104) according to the manufacturer's protocol.

Subsequently, bisulfite converted DNA was amplified by PCR using OneTaq HotStart DNA Polymerase (New England Biolabs, Reference M0481) with touch-down thermocycler

program. Each PCR reaction was performed in triplicate. The amplified PCR products were subsequently subjected to Sanger sequencing (Genewiz), and the levels of modification at single nucleotides were quantified by EditR<sup>13</sup>. The primers used in bisulfite PCR are detailed in **Supplemental Table 1**.

## 5 **Chromatin immunoprecipitation**

Chromatin immunoprecipitation (ChIP) of frozen muscle biopsies was performed using MAGnify Chromatin Immunoprecipitation System (Invitrogen) according to the manufacturer's protocol with minor modifications. First, 50-100 mg muscle tissues were minced quickly on ice by scissor, and homogenized thoroughly by sequential uses of 16G, 18G, and 21G needle. Then, homogenates were immediately fixed in 1% formaldehyde for 10 minutes, quenched in 0.125M glycine, and washed twice in ice-cold PBS. Subsequently, the lysates were sonicated for 15 cycles of 30 seconds ON, 30 seconds OFF using Bioruptor Pico (Diagenode). Diluted lysates at this step were used as Input Control. The magnetic beads, which were already incubated with antibodies, were then incubated with the sheared chromatin for 2 hours at 4°C on the orbital shaker. After that, the formaldehyde crosslinks of the bound chromatin and Input Control were reversed and un-crosslinked DNA could be purified. Purified DNA was subjected to qPCR using SYBR Green PCR assays (Thermo Fisher Scientific). Each PCR reaction was performed in duplicate. Level of Input Control DNA was used to normalize the data across samples. Besides, ChIP reactions using rabbit and mouse IgG were also used as negative control. The antibodies and PCR primers used in ChIP-PCR were detailed in **Supplemental Table 1**. The location of ChIP-PCR primers is shown in **Supplemental Figure 2E**.

## **RNA expression analysis**



Total RNA was extracted from frozen muscles or cells using Trizol (Thermo Fisher Scientific). DNA contamination from RNA samples was subsequently removed by TURBO DNA-free kit (Thermo Fisher Scientific). For the measurement of *miRNA expression*, 500 ng of total RNA were reverse-transcribed using TaqMan™ MicroRNA Reverse Transcription Kit (Thermo Fisher Scientific). Quantitative PCR was performed using LightCycler 480 system (Roche), with the Applied Biosystems TaqMan MicroRNA Assays (Thermo Fisher Scientific), according to the manufacturer's protocol. Each PCR reaction was performed in duplicate. Results obtained with miR-93-5p or U6 small nuclear RNA were used to normalize data across samples. For the measurement of *gene expression*, 1000 ng of total RNA was reverse-transcribed using a mixture of random oligonucleotides and oligo-dT and RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). Quantitative PCR was performed using LightCycler 480 system (Roche) with the SYBR™ Green PCR assays (Thermo Fisher Scientific) or Taqman Gene Expression Assay (Thermo Fisher Scientific). Each PCR reaction was performed in duplicate. Results obtained with Rplp0 (for muscle samples) or Acta1 (for *in vitro* cells) were used to normalize the data across samples. Relative expression fold change was calculated using  $2^{-\Delta\Delta CT}$  method, as previously described<sup>14</sup>. Primers used in the study are presented in **Supplemental Table 1**.

### RNA sequencing and transcriptomic analysis

RNA quality was first examined by Bioanalyzer 2100 (Agilent). Samples with RNA integrity number greater than 7.5 were then subjected to RNA sequencing (Genewiz). The sequencing libraries were prepared using the Stranded Total RNA Library Prep Kit (Illumina) and sequenced according to the Illumina protocol by NovaSeq instrument (Illumina), resulting in approximately 20M paired-end reads per library. Filtration and quality control was done by fastp<sup>15</sup>. The pair-end reads were subsequently mapped into GRCm38/mm10 genome by

HISAT2<sup>16</sup>, and count tables were produced by FeatureCount<sup>17</sup>. Differentially expressed genes were identified by DESeq2 R package<sup>4</sup>. Pathway analysis was performed in R-Studio (version 4.0.3), either by over-representation methods using Gene Ontology and ReactomePA or functional class scoring using Geneset Enrichment Analysis (GSEA). The list of R packages used in the analysis can be found in **Supplemental Table 1**.

### **Cell culture and *in vitro* study**

Myoblast C2C12 cells were maintained in the proliferating medium containing DMEM (Thermo Fisher Scientific) supplied with 10% Fetal Bovine Serum and 1X Gentamycin at 37°C, 5% CO<sub>2</sub>. Human induced pluripotent stem cells (hiPSCs) were maintained in mTeSR medium (Stemcell Technologies, Reference 05850) on Matrigel-coated plate (Corning, Reference 356230). To differentiate hiPSCs into skeletal muscle lineage, 2D directed differentiation protocol was used as previously described<sup>18</sup>. The hiPSCs were placed in three consecutive defined media as followed: SKM01 (AMSBio) from day 0 to 10, SKM02 (AMSBio) from day 10 to 17, and SKM03 (AMSBio) from day 17 to 20 (**Supplemental Figure 5B**).

### **Genomic deletion using the CRISPR/Cas9 and screening for bi-allelic deletion clones**

Single-guide RNAs (sgRNAs) were designed by GPP sgRNA Designer<sup>9</sup> and synthetic oligos with chemical modifications (2'-O-Methyl at 3' first and last bases, 3' phosphorothioate bonds between first 3 and last 2 bases) were synthesized by Synthego. Different combinations of sgRNAs targeting two ends of IG-DMR region were tested in 911 human cells to select sgRNAs with the highest cutting efficacy. Selected sgRNAs were then co-transfected with PX458 plasmid (Addgene #48138), which contains the expression cassettes of *S. pyogenes* Cas9 and GFP, into hiPSCs by Lipofectamine 3000 (Thermo Fisher Scientific) according to manufacturer instruction. After 24 hours post-transfection, single GFP<sup>+</sup> cells were sorted by Astrios Cell Sorter (Beckman Coulter) directly in pre-warmed mTeSR medium supplemented

with 10% CloneR (Stemcell technologies, Reference 5888) and hES Cell Cloning & Recovery Supplement (Stemgent, Reference 01-0014-500, dilution 1/2000). The single clones were kept at 37°C for 7 days, and the medium was changed every 2-3 days. Subsequently, genomic DNA of hiPSC clones was extracted by QuickExtract DNA Extraction Solution (Epicentre) and subjected to three PCR reactions with three sets of primers to screen for bi-allelic IG-DMR deletion (IG-DMR<sup>-/-</sup>). The positions of primers and the sizes of the PCR amplicons were illustrated in **Supplemental Figure 5A**. The sequences of selected sgRNAs and PCR primers for screening were detailed in **Supplemental Table 1-2**. We selected two single clones with no IG-DMR deletion in both alleles from the same screening process, used as control (IG-DMR<sup>+/+</sup>) in subsequent experiments. Off-targets of 2 sgRNAs used in this study were identified by CHOPCHOP<sup>10</sup> and detailed in **Supplemental Table 2-3**. The absence of any off-target in all clones used in this study were validated by Sanger sequencing (Genewiz).

### **Immunohistofluorescence and histochemistry staining**

The transversal sections of 8-μm thickness were prepared from frozen muscles in the cryostat (Leica). The sections were subsequently fixed in 4% methanol-free paraformaldehyde for 10 minutes before blocked in the Blocking Buffer 10% Goat Serum (Gibco) in 1X PBS for 1 hour at room temperature. The blocked tissues were then incubated with primary antibodies in 1% Goat Serum (Gibco) in 1X PBS overnight at 4 °C. Samples were washed and incubated with Alexa-conjugated secondary antibodies (Life Technologies, dilution: 1/1000) in 1% Goat Serum (Gibco) in 1X PBS for 45 min at room temperature. After rewashing in 1X PBS, samples were mounted in DAPI Fluoromount-G (Southern Biotech) and stored at 4 °C. For enzyme histochemistry staining of succinate dehydrogenase (SDH) and Cytochrome C oxidase (COX) activities, freshly prepared slides were used and stained by using commercial kits (Bio-Optica, Reference 30114LY and 30115LY, respectively) according to the manufacturer's protocols.

Images were acquired with confocal microscopy TCS-SP8 (Leica) or AxioScan Slide Scanner (Zeiss).

### ***In situ* hybridization of miRNAs in skeletal muscle**

For miRNA *in situ* hybridization (ISH), muscles were dissected and immediately fixed in 10% neutral-buffed formalin overnight before embedded in paraffin blocks. Transversal sections of 4- $\mu$ m thickness were obtained in the Microtome (Leica). The ISH of miR-127-3p and miR-379-5p were performed by miRCURY LNA miRNA ISH Optimization Kit (FFPE) 1 (Qiagen, Reference 339451), according to the manufacturer's protocol. All miRNA probes are double-digoxigenin-labeled and hybridized at a final concentration of 40 nM at 53°C for 1 hour. Probe with scramble sequence was used as the negative control. Nuclei were counterstained with Nuclear Fast Red (Fluka, Reference 60700). The miRNA probe sequences are shown in **Supplemental Table 1**.

### **Western blotting**

Proteins were extracted from tissues or cells by RIPA buffer (Thermo Scientific) supplemented with Protease Inhibitor Cocktails (Complete PIC, Roche) and Benzonase 1:1000 (Millipore). Total protein concentration was measured by using Pierce BCA Protein Assay (Thermo Fisher Scientific). Equal amounts of protein were then loaded and separated by precast 4-12% Bis-Tris polyacrylamide gel (Thermo Fisher Scientific). Subsequently, the protein was transferred to a nitrocellulose membrane with the iBlot2 Dry Blotting system (Thermo Fisher Scientific). For detecting the proteins of interest, the membrane was blocked in Odyssey® Blocking Buffer (LI-COR) for 1 hour at room temperature before incubated with primary antibodies diluted in 50% Odyssey® Blocking Buffer overnight at 4 °C. After washed in 1X PBST, the membrane was incubated with secondary antibodies 1/5000 diluted in the 50% Odyssey® Blocking Buffer for 1 hour at room temperature. The membrane was then rewashed and blotting signals were

acquired in the Odyssey Infrared Imaging system. Total protein (for muscle samples) measured by Revert 700 Total Protein (LI-COR) (for muscle samples) or Actin (for *in vitro* cells) was used as loading controls for quantification. Details of antibodies used in this study are presented in **Supplemental Table 1**.

## 5 **Measurement of Citrate Synthase Activities**

Citrate Synthase (CS) activity of muscle extracts was determined by Citrate Synthase Assay Kit (Sigma-Aldrich, Reference CS0720) according to the manufacturer's protocol. 5-10 mg of muscle tissues were initially used and 5 µg of protein extract was used to measure CS activity.

## **Measurement of ATP concentration**

- 10 ATP concentration of the muscle biopsies was determined by ATP Assay Kit (Abcam, Reference ab83355) according to the manufacturer's protocol. 5-10 mg of muscle tissues were used in the assay. The precise mass of muscle tissues was noted and subsequently used to normalize across samples.

## **Measurement of mitochondrial and viral DNA**

- 15 Total DNA was extracted from 5-10 mg of muscle tissues by using QIAamp DNA Mini Kit (Qiagen, Reference 51304) according to the manufacturer's protocol. Purified DNA was subjected to qPCR using SYBR Green PCR assays (Thermo Fisher Scientific). Levels of genomic DNA were used to normalize data across samples. Primers amplifying genomic DNA, mitochondrial DNA and DNA from AAV vectors were detailed in **Supplemental Table 1**.

## 20 **Measurement of mitochondrial OxPhos enzymatic activities**

Enzymatic activities of complex I (NADH:ubiquinone oxidoreductase, rotenone-sensitive activity), II (succinate dehydrogenase, malonate-sensitive activity), III (decylubiquinol

cytochrome c oxidoreductase, antimycin A - sensitive activity), IV (cytochrome c oxidase, KCN-sensitive activity); combined activities of complex I+III (NADH cytochrome c oxidoreductase, rotenone-sensitive activity) and II+III (succinate cytochrome c reductase, malonate-sensitive activity); and citrate synthase (CS) was determined as described<sup>19</sup>. On the other hand, complex V (ATP synthase, oligomycin-sensitive activity) activity was measured according to Benit et al., 2006<sup>20</sup>. The measurement was performed in muscle homogenates for skeletal muscles and isolated mitochondria for hiPSC-derived myotubes. Muscle homogenates and myotube mitochondria were subjected to three freeze-thaw cycles to increase rotenone sensitivity. Subsequently, the OxPhos and CS activities were determined spectrophotometrically with Cary 60 UV-Vis spectrometer (Agilent) or Spark Cyto (Tecan). CS activities were used to normalize across samples as an indicator of mitochondrial mass.

## REFERENCES

1. Castel D, Baghdadi MB, Mella S, Gayraud-Morel B, Marty V, Cavaillé J *et al.* Small-RNA sequencing identifies dynamic microRNA deregulation during skeletal muscle lineage progression. *Sci Rep* 2018;**8**:4208.
2. Roberts TC, Blomberg KE, McClorey G, Andaloussi SE, Godfrey C, Betts C *et al.* Expression Analysis in Multiple Muscle Groups and Serum Reveals Complexity in the MicroRNA Transcriptome of the mdx Mouse with Implications for Therapy. *Mol Ther Nucleic Acids* 2012;**1**:e39.
3. Pescatori M, Broccolini A, Minetti C, Bertini E, Bruno C, D'Amico A *et al.* Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. *Faseb J* 2007;**21**:1210–1226.
4. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014;**15**.
5. Yu G, He QY. ReactomePA: An R/Bioconductor package for reactome pathway analysis and visualization. *Mol Biosyst* 2016;**12**:477–479.
6. Durinck S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration of genomic datasets with the R/ Bioconductor package biomaRt. *Nat Protoc* 2009;**4**:1184–1191.
7. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA *et al.* Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005;**102**:15545–15550.
8. Pajak M. miRNAatp: miRNAatp: microRNA Targets - Aggregated Predictions. in miRNAatp: miRNAatp: microRNA Targets - Aggregated Predictions. <https://rdrr.io/bioc/miRNAatp/man/miRNAatp.html>. Accessed 30 July 2021.

9. Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF *et al.* Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. *Nat Biotechnol* 2016;**34**:184–191.
- 5 10. Labun K, Montague TG, Krause M, Torres Cleuren YN, Tjeldnes H, Valen E. CHOPCHOP v3: Expanding the CRISPR web toolbox beyond genome editing. *Nucleic Acids Res* 2019;**47**:W171–W174.
11. Lostal W, Kodippili K, Yue Y, Duan D. Full-length dystrophin reconstitution with adeno-associated viral vectors. *Hum Gene Ther* 2014;**25**:552–62.
- 10 12. Liu L, Cheung TH, Charville GW, Rando TA. Isolation of skeletal muscle stem cells by fluorescence-activated cell sorting. *Nat Protoc* 2015;**10**:1612–24.
13. Kluesner MG, Nedveck DA, Lahr WS, Garbe JR, Abrahante JE, Webber BR *et al.* EditR: A Method to Quantify Base Editing from Sanger Sequencing. *Cris J* 2018;**1**:239–250.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2- $\Delta\Delta$ CT method. *Methods* 2001;**25**:402–408.
- 15 15. Chen S, Zhou Y, Chen Y, Gu J. Fastp: An ultra-fast all-in-one FASTQ preprocessor. In: *Bioinformatics*. Oxford University Press; 2018. pp. i884–i890.
16. Kim D, Langmead B, Salzberg SL. HISAT: A fast spliced aligner with low memory requirements. *Nat Methods* 2015;**12**:357–360.
- 20 17. Liao Y, Smyth GK, Shi W. FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 2014;**30**:923–930.
18. Caron L, Kher D, Lee KL, McKernan R, Dumevska B, Hidalgo A *et al.* A Human Pluripotent Stem Cell Model of Facioscapulohumeral Muscular Dystrophy-Affected Skeletal Muscles. *Stem Cells Transl Med* 2016;**5**:1145–1161.
- 25 19. Spinazzi M, Casarin A, Pertegato V, Salviati L, Angelini C. Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. *Nat Protoc* 2012;**7**:1235–1246.
20. Bénit P, Goncalves S, Philippe Dassa E, Brière J-J, Martin G, Rustin P. Three spectrophotometric assays for the measurement of the five respiratory chain complexes in minuscule biological samples. *Clin Chim Acta* 2006;**374**:81–6.

30